| Literature DB >> 33840678 |
Fuminori Tanihara1,2, Maki Hirata1, Takeshige Otoi1.
Abstract
Genetically modified animals, especially rodents, are widely used in biomedical research. However, non-rodent models are required for efficient translational medicine and preclinical studies. Owing to the similarity in the physiological traits of pigs and humans, genetically modified pigs may be a valuable resource for biomedical research. Somatic cell nuclear transfer (SCNT) using genetically modified somatic cells has been the primary method for the generation of genetically modified pigs. However, site-specific gene modification in porcine cells is inefficient and requires laborious and time-consuming processes. Recent improvements in gene-editing systems, such as zinc finger nucleases, transcription activator-like effector nucleases, and the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (CRISPR/Cas) system, represent major advances. The efficient introduction of site-specific modifications into cells via gene editors dramatically reduces the effort and time required to generate genetically modified pigs. Furthermore, gene editors enable direct gene modification during embryogenesis, bypassing the SCNT procedure. The application of gene editors has progressively expanded, and a range of strategies is now available for porcine gene engineering. This review provides an overview of approaches for the generation of genetically modified pigs using gene editors, and highlights the current trends, as well as the limitations, of gene editing in pigs.Entities:
Keywords: Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (CRISPR/Cas); Gene editing; Pig; Transcription activator-like effector nuclease (TALEN); Zinc finger nuclease (ZFN)
Mesh:
Year: 2021 PMID: 33840678 PMCID: PMC8238678 DOI: 10.1262/jrd.2021-025
Source DB: PubMed Journal: J Reprod Dev ISSN: 0916-8818 Impact factor: 2.214
Fig. 1.Schematic of major methods for generating genetically modified pigs using gene editors.
Gene-edited pigs to establish models for intractable diseases
| Disease | Gene targeted | Method | Editor | Reference | |
|---|---|---|---|---|---|
| Cancer | DAZL, APC | CT | TALEN, CRISPR | Tan | [ |
| RUNX3 | SCNT | CRISPR | Kang | [ | |
| TP53 | SCNT | TALEN | Shen | [ | |
| TP53 | EP | CRISPR | Tanihara | [ | |
| Cardiomyopathy | MYH7 | SCNT | TALEN | Montag | [ |
| SGCD | SCNT | TALEN | Matsunari | [ | |
| Cryopyrin-associated periodic syndrome | NLRP3 | SCNT | CRISPR | Li | [ |
| Diabetes | INS | SCNT | CRISPR | Cho | [ |
| IAPP | SCNT | CRISPR | Zou | [ | |
| PDX1 | EP | CRISPR | Tanihara | [ | |
| Duchenne muscular dystrophy | DMD | CMI | CRISPR | Yu | [ |
| Familial hypercholesterolemia | LDLR | SCNT | TALEN | Carlson | [ |
| ApoE, LDLR | SCNT | CRISPR | Huang | [ | |
| Human Waardenburg syndrome | MITF | SCNT, CMI | CRISPR | Wang | [ |
| MITF | CMI | CRISPR | Hai | [ | |
| Hemophilia B | F9 | SCNT | CRISPR | Chen | [ |
| Huntington’s disease | HTT | SCNT | CRISPR | Yan | [ |
| Hutchinson–Gilford progeria syndrome | NLRP3 | SCNT | CRISPR | Dorado | [ |
| Leigh syndrome | SURF1 | SCNT | TALEN, CRISPR | Quadalti | [ |
| Marfan syndrome | FBN1 | SCNT | ZFN | Umeyama | [ |
| Ornithine transcarbamylase deficiency | OTC | SCNT | TALEN | Matsunari | [ |
| Parkinson’s disease | GGTA1, Parkin, DJ-1 | SCNT | TALEN | Yao | [ |
| TYR, PINK1, PARK2 | SCNT | CRISPR | Zhou | [ | |
| Parkin, DJ-1, PINK1 | CMI | CRISPR | Wang | [ | |
| SCNA | SCNT | CRISPR | Zhu | [ | |
| Phenylketonuria | PAH | CMI | CRISPR | Koppes | [ |
| Polycystic kidney disease | PKD1 | SCNT | ZFN | He | [ |
| von Willebrand disease | vWF | CMI | CRISPR | Hai | [ |
| X-linked severe combined immunodeficiency | IL2RG | SCNT | ZFN | Watanabe | [ |
| IL2RG | SCNT, CMI | CRISPR | Kang | [ | |
| IL2RG | CMI | CRISPR | Chen | [ | |
| IL2RG | SCNT | CRISPR | Ren | [ | |
CT, chromatin transfer; SCNT, somatic cell nuclear transfer; CMI, cytoplasmic microinjection; EP, electroporation.
Fig. 2.Trends in recent reports on generating genetically modified pigs using gene editors. Number of PubMed articles reporting the generation of genetically modified pigs using gene editors over the last 10 years (2011–2020; search terms: “pig,” “ZFN,” “TALEN,” and “CRISPR”). (A) Total number of articles. (B) Changes in the number of articles per year, including information on gene editors and the method used to generate mutant pigs. SCNT, somatic cell nuclear transfer; CMI, cytoplasmic microinjection into zygotes/embryos; EP, electroporation into zygotes/embryos; CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR-associated protein; TALEN, transcription activator-like effector nuclease; ZFN, zinc finger nuclease. Studies using multiple gene editors or multiple methods used to generate mutant pigs were classified into each relevant category and were therefore double-counted. Studies using CRISPR/Cas-related methods (e.g., Cas9 nickase and FokI-dCas9) were classified under “CRISPR.”
Gene editing efficiency and mosaicism of resulting offspring/fetuses in studies using cytoplasmic microinjection- or electroporation-mediated gene editing
| Reference | Method | Gene targeted | Introduced components | Gene-edited/total offspring and fetuses (%) | Mosaic/gene-edited (%) | ||||
|---|---|---|---|---|---|---|---|---|---|
| ZFN | |||||||||
| Lillico | [ | CMI | RELA | mRNA | 1/9 | (11.1) | 0/1 | (0) | |
| TALEN | |||||||||
| Lillico | [ | CMI | RELA | mRNA | 8/39 | (20.5) | 2/8 | (25.0) | |
| Wang | [ | CMI | B2M | mRNA | 6/7 | (85.7) | 3/6 | (50.0) | |
| CRISPR | |||||||||
| Hai | [ | CMI | vWF | Cas9 mRNA and gRNA | 11/16 | (68.8) | 2 or more/11 | ( - ) | |
| Whitworth | [ | CMI | CD163 | Cas9 mRNA and gRNA | 4/4 | (100) | 0/4 | (0) | |
| CD1D | Cas9 mRNA and gRNA | 4/4 | (100) | 1/4 | (25.0) | ||||
| Wang | [ | CMI | MITF | Cas9 mRNA and gRNA | 2/2 | (100) | 0/2 | (0) | |
| Zhou | [ | CMI | Sox10 (point mutation) | Cas9 mRNA and gRNA | 12/12 | (100) | 8/12 | (66.7) | |
| Peng | [ | CMI | recombinant human serum albumin (knock-in) | Cas9 mRNA and gRNA | 16/16 | (100) | 1/16 | (6.25) | |
| Wang | [ | CMI | Parkin, DJ-1, PINK1 | Cas9 mRNA and gRNA | 2/2 | (100) | 0/2 | (0) | |
| Petersen | [ | CMI | GGTA1 | Plasmid | 11/12 | (91.7) | 4/11 | (36.4) | |
| Yu | [ | CMI | DMD | Cas9 mRNA and gRNA | 1/2 | (50.0) | 1/1 | (100) | |
| Kang | [ | CMI | IL2RG | Cas9 mRNA and gRNA | 4/6 | (66.7) | 0/4 | (0) | |
| Park | [ | CMI | NANOS2 | Cas9 mRNA and gRNA | 18/18 | (100) | 5/18 | (27.8) | |
| Wu | [ | CMI | PDX1 | Cas9 mRNA and gRNA | 3/9 | (33.3) | 2/3 | (66.7) | |
| Hai | [ | CMI | MITF | Cas9 mRNA and gRNA | 2/2 | (100) | 0/2 | (0) | |
| Hinrichs | [ | CMI | GHR | Cas9 mRNA and gRNA | 3/8 | (37.5) | 0/3 | (0) | |
| Xiang | [ | CMI | IGF2 | Nickase mRNA and gRNA | 6/6 | (100) | 3/6 | (50.0) | |
| Whitworth | [ | CMI | ANPEP | Cas9 mRNA and gRNA | 13/18 | (72.2) | 3/13 | (23.1) | |
| Tu | [ | CMI | CMP-N-glycolylneuraminic acid hydroxylase | Cas9 mRNA and gRNA | 5/6 | (83.3) | 3/5 | (60.0) | |
| Chen | [ | CMI | TYR, IL2RG, RAG1 | Cas9 mRNA and gRNA | 15/16 | (93.8) | 5/15 | (33.3) | |
| Tanihara | [ | EP | MSTN | Cas9 protein and gRNA | 9/10 | (90.0) | 4/9 | (44.4) | |
| Tanihara | [ | EP | TP53 | Cas9 protein and gRNA | 6/9 | (66.7) | 4/6 | (66.7) | |
| Tanihara | [ | EP | PDX | Cas9 protein and gRNA | 9/10 | (90.0) | 4/9 | (44.4) | |
| Tanihara | [ | EP | GGTA1 | Cas9 protein and gRNA | 5/6 | (83.3) | 2/5 | (40.0) | |
CMI, cytoplasmic microinjection; EP, electroporation. In this table, offspring/fetuses carrying three alleles or more, or extreme deviations in allele frequencies are denoted as mosaic.